Bernstein Reiterates Market Perform Rating on Pfizer (PFE)

Bernstein SocGen Group analyst Courtney Breen reiterated a Market Perform rating and $30.00 price target on Pfizer (NYSE: PFE).

The analyst commented: "The cards are on the table & only $6B remains in the envelope. While there are some read-outs in ‘26, the main focus will be on - can PFE initiate the right studies for the assets they’ve acquired (PD1xVEGF, incretins) & build confidence in investors that these deals were the right ones. Retain MP at $30 PT."

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $25.65 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades New Oriental Education (EDU) to Buy
• Bernstein SocGen Group Starts Keurig Dr Pepper (KDP) at Outperform, 'outstanding Functional Beverages portfolio'
• Belden prices $1.85 billion term loan to fund RUCKUS acquisition